According to Blueprint Medicines 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 27.2559. At the end of 2023 the company had a P/S ratio of 22.5.
Year | P/S ratio | Change |
---|---|---|
2023 | 22.5 | 75.02% |
2022 | 12.8 | -63.29% |
2021 | 35.0 | 344.43% |
2020 | 7.87 | -86.73% |
2019 | 59.3 | 11.29% |
2018 | 53.3 | -65.14% |
2017 | 153 | 357.88% |
2016 | 33.4 | -46.58% |
2015 | 62.5 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pacific Biosciences
PACB | 2.54 | -90.68% | ๐บ๐ธ USA |
OPKO Health
OPK | 1.05 | -96.15% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | N/A | N/A | ๐บ๐ธ USA |
Isoray
ISR | 11.9 | -56.22% | ๐บ๐ธ USA |